Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14351404 | 0.97 | CHRM2 (0.36) | CHRM2CHRM4CHRM1CHRM3FFAR3 | |
| Hydrochloric Acid SCHEMBL4198612 | 0.97 | CHRM2 (0.36) | CHRM2CHRM4CHRM1CHRM3FFAR3 | |
| SCHEMBL205297 | 0.91 | CHRM2 (0.44) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL31731969 | 0.91 | CHRM2 (0.44) | CHRM2CHRM4CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL2421629 | 0.89 | CHRM2 (0.42) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL3951763 | 0.85 | CHRM2 (0.39) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL592855 | 0.83 | FFAR3 (0.35) | FFAR3 | |
| Hydrochloric Acid SCHEMBL9051821 | 0.83 | CHRM2 (0.38) | CHRM2CHRM4CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL592784 | 0.81 | FFAR3 (0.33) | CHRM2CHRM1CHRM3FFAR3 | |
| SCHEMBL7981263 | 0.77 | CHRM2 (0.40) | CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0287356-B1 | Bridgehead substituted azabicyclic derivatives | BEECHAM GROUP PLC (GB) | 1996-01-24 | — | — | EP | claimed |
| US-5132316-A | Cognition activators | BEECHAM GROUP P.L.C. (GB) | 1992-07-21 | — | — | US | claimed |
| US-20240390383-A1 | DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | Zevra Denmark A/S (DK) | 2024-11-28 | — | — | US | disclosed |
| EP-4408838-A1 | DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | Zevra Denmark A/S (DK) | 2024-08-07 | — | — | EP | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-118076599-A | Dioxazines and their use in the treatment of GBA related diseases | 泽拉丹麦有限公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146989-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023053007-A1 | DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | KEMPHARM DENMARK A/S (DK) | 2023-04-06 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220213090-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| US-20130102583-A1 | CEPHEM COMPOUND HAVING CATECHOL GROUP | SHIONOGI & CO., LTD. (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| EP-2557082-A1 | CEPHEM COMPOUND HAVING CATECHOL GROUP | Shionogi & Co., Ltd. (JP) | 2013-02-13 | — | — | EP | disclosed |
| EP-2499120-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | Novadex Pharmaceuticals AB (SE) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| WO-2009029375-A1 | NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| EP-0287356-B1 | Bridgehead substituted azabicyclic derivatives | BEECHAM GROUP PLC (GB) | 1996-01-24 | — | — | EP | disclosed |
| EP-0287356-A2 | Bridgehead substituted azabicyclic derivatives | BEECHAM GROUP PLC (GB) | 1988-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213090-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CHRM2 1332/4885CHRM4 2487/4885CHRM1 2097/4885 |
| US-20130102583-A1 | CEPHEM COMPOUND HAVING CATECHOL GROUP | COMT, EZH1, SETD7 | CHRM2 453/4885CHRM4 726/4885CHRM1 203/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CHRM2 13/4885CHRM4 138/4885CHRM1 7/4885 |
| US-20240390383-A1 | DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | GBA1, GBA2, GBA3 | CHRM2 3369/4885CHRM4 2634/4885CHRM1 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.